Glenmark Pharmaceuticals Limited commits to reduce absolute scope 1 and 2 GHG emissions 35% by FY2035 from a FY2021 base year.* Glenmark Pharmaceuticals Limited also commits to reduce scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, downstream transportation and distribution, and investments 28% per ton of pharmaceutical products within the same timeframe. *The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks.